_id
69109657ccc777a4e85d5b4f
Ticker
EMBT
Name
Ember Therapeutics Inc
Exchange
PINK
Address
135 East 57th Street, New York, NY, United States, 10022
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.embertx.com
Description
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport's syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease. The company also holds approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York.
Last Close
0.0001
Volume
-
Current Price
0.0001
Change
0
Last Updated
2026-01-03T10:56:55.454Z
Image
-
Ipo Date
-
Market Cap
4000
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2015-09-30
Revenue
0
Cost Of Revenue
0
Gross Profit
0
Operating Expenses
-252
Operating Income
252
Interest Expense
1603
Pretax Income
-1351
Net Income
-1351
Eps
-0.0003643964935940661
Dividends Per Share
-
Shares Outstanding
40000000
Income Tax Expense
0
EBITDA
252
Operating Margin
-
Total Other Income Expense Net
-1603
Cash
2302
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
2302
Property Plant Equipment
-
Total Assets
2302
Payables
1500
Short Term Debt
214616
Long Term Debt
-
Total Liabilities
254803
Equity
-252501
Bs_currency_symbol
USD
Depreciation
-
Change In Working Capital
-4672
Cash From Operations
-6023
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
5500
Net Change In Cash
-523
Cf_currency_symbol
USD
PE
-
PB
-0.0014683110165900333
ROE
0.5350473859509468
ROA
-58.68809730668983
FCF
-6023
Fcf Percent
-
Piotroski FScore
0
Health Score
23
Deep Value Investing Score
2.5
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
0.5
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
1.5
Quality Investing Score
1
Value Investing Score
1
Quarters > 0 > quarter
2015-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
0
Quarters > 0 > income Statement > gross Profit
0
Quarters > 0 > income Statement > operating Expenses
-252
Quarters > 0 > income Statement > operating Income
252
Quarters > 0 > income Statement > interest Expense
1603
Quarters > 0 > income Statement > pretax Income
-1351
Quarters > 0 > income Statement > net Income
-1351
Quarters > 0 > income Statement > eps
-0.0003643964935940661
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
3707500
Quarters > 0 > income Statement > income Tax Expense
0
Quarters > 0 > income Statement > EBITDA
252
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-1603
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
2302
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
2302
Quarters > 0 > balance Sheet > property Plant Equipment
-
Quarters > 0 > balance Sheet > total Assets
2302
Quarters > 0 > balance Sheet > payables
1500
Quarters > 0 > balance Sheet > short Term Debt
214616
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
254803
Quarters > 0 > balance Sheet > equity
-252501
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-1351
Quarters > 0 > cash Flow > depreciation
-
Quarters > 0 > cash Flow > change In Working Capital
-4672
Quarters > 0 > cash Flow > cash From Operations
-6023
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
5500
Quarters > 0 > cash Flow > net Change In Cash
-523
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.0003643964935940661
Quarters > 0 > ratios > PB
-0.0014683110165900333
Quarters > 0 > ratios > ROE
0.5350473859509468
Quarters > 0 > ratios > ROA
-58.68809730668983
Quarters > 0 > ratios > FCF
-6023
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
23
Quarters > 1 > quarter
2015-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
0
Quarters > 1 > income Statement > gross Profit
0
Quarters > 1 > income Statement > operating Expenses
5844
Quarters > 1 > income Statement > operating Income
-5844
Quarters > 1 > income Statement > interest Expense
1556
Quarters > 1 > income Statement > pretax Income
-7400
Quarters > 1 > income Statement > net Income
-7400
Quarters > 1 > income Statement > eps
-0.0019959541469993258
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
3707500
Quarters > 1 > income Statement > income Tax Expense
0
Quarters > 1 > income Statement > EBITDA
-5844
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-1556
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
2825
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
2825
Quarters > 1 > balance Sheet > property Plant Equipment
-
Quarters > 1 > balance Sheet > total Assets
2825
Quarters > 1 > balance Sheet > payables
7775
Quarters > 1 > balance Sheet > short Term Debt
209116
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
253975
Quarters > 1 > balance Sheet > equity
-251150
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-7400
Quarters > 1 > cash Flow > depreciation
-
Quarters > 1 > cash Flow > change In Working Capital
5881
Quarters > 1 > cash Flow > cash From Operations
-1519
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
2000
Quarters > 1 > cash Flow > net Change In Cash
481
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.0019959541469993258
Quarters > 1 > ratios > PB
-0.0014762094365916784
Quarters > 1 > ratios > ROE
2.946446346804698
Quarters > 1 > ratios > ROA
-261.94690265486724
Quarters > 1 > ratios > FCF
-1519
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
26
Quarters > 2 > quarter
2015-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
0
Quarters > 2 > income Statement > gross Profit
0
Quarters > 2 > income Statement > operating Expenses
3790
Quarters > 2 > income Statement > operating Income
-3790
Quarters > 2 > income Statement > interest Expense
1490
Quarters > 2 > income Statement > pretax Income
-5280
Quarters > 2 > income Statement > net Income
-5280
Quarters > 2 > income Statement > eps
-0.0014241402562373568
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
3707500
Quarters > 2 > income Statement > income Tax Expense
0
Quarters > 2 > income Statement > EBITDA
-3790
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-1490
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
2344
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
2344
Quarters > 2 > balance Sheet > property Plant Equipment
-
Quarters > 2 > balance Sheet > total Assets
2344
Quarters > 2 > balance Sheet > payables
3450
Quarters > 2 > balance Sheet > short Term Debt
207116
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
246094
Quarters > 2 > balance Sheet > equity
-243750
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-5280
Quarters > 2 > cash Flow > depreciation
-
Quarters > 2 > cash Flow > change In Working Capital
940
Quarters > 2 > cash Flow > cash From Operations
-4340
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
6500
Quarters > 2 > cash Flow > net Change In Cash
2160
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.0014241402562373568
Quarters > 2 > ratios > PB
-0.0015210256410256413
Quarters > 2 > ratios > ROE
2.166153846153846
Quarters > 2 > ratios > ROA
-225.25597269624575
Quarters > 2 > ratios > FCF
-4340
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
25
Quarters > 3 > quarter
2014-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
0
Quarters > 3 > income Statement > gross Profit
0
Quarters > 3 > income Statement > operating Expenses
4548
Quarters > 3 > income Statement > operating Income
-4548
Quarters > 3 > income Statement > interest Expense
1516
Quarters > 3 > income Statement > pretax Income
-6064
Quarters > 3 > income Statement > net Income
-6064
Quarters > 3 > income Statement > eps
-0.001635603506405934
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
3707500
Quarters > 3 > income Statement > income Tax Expense
0
Quarters > 3 > income Statement > EBITDA
-4548
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-1516
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
184
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
184
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
184
Quarters > 3 > balance Sheet > payables
4000
Quarters > 3 > balance Sheet > short Term Debt
200616
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
238654
Quarters > 3 > balance Sheet > equity
-238470
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-6064
Quarters > 3 > cash Flow > depreciation
-
Quarters > 3 > cash Flow > change In Working Capital
2916
Quarters > 3 > cash Flow > cash From Operations
-3148
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
1150
Quarters > 3 > cash Flow > net Change In Cash
-1998
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.001635603506405934
Quarters > 3 > ratios > PB
-0.001554702897639116
Quarters > 3 > ratios > ROE
2.5428775107980037
Quarters > 3 > ratios > ROA
-3295.652173913044
Quarters > 3 > ratios > FCF
-3148
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
26
Annuals > 0 > quarter
2014-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
0
Annuals > 0 > income Statement > gross Profit
0
Annuals > 0 > income Statement > operating Expenses
17421
Annuals > 0 > income Statement > operating Income
-17421
Annuals > 0 > income Statement > interest Expense
5821
Annuals > 0 > income Statement > pretax Income
-23242
Annuals > 0 > income Statement > net Income
-23242
Annuals > 0 > income Statement > eps
-0.006268914362778153
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
3707500
Annuals > 0 > income Statement > income Tax Expense
0
Annuals > 0 > income Statement > EBITDA
-17421
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-5821
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
184
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
184
Annuals > 0 > balance Sheet > property Plant Equipment
-
Annuals > 0 > balance Sheet > total Assets
184
Annuals > 0 > balance Sheet > payables
4000
Annuals > 0 > balance Sheet > short Term Debt
200616
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
238654
Annuals > 0 > balance Sheet > equity
-238470
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-23242
Annuals > 0 > cash Flow > depreciation
-
Annuals > 0 > cash Flow > change In Working Capital
6521
Annuals > 0 > cash Flow > cash From Operations
-16721
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
15650
Annuals > 0 > cash Flow > net Change In Cash
-1071
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-0.006268914362778153
Annuals > 0 > ratios > PB
-0.001554702897639116
Annuals > 0 > ratios > ROE
9.746299324862665
Annuals > 0 > ratios > ROA
-12631.521739130434
Annuals > 0 > ratios > FCF
-16721
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
22
Annuals > 1 > quarter
2013-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
0
Annuals > 1 > income Statement > gross Profit
0
Annuals > 1 > income Statement > operating Expenses
11077
Annuals > 1 > income Statement > operating Income
-11077
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-16333
Annuals > 1 > income Statement > net Income
-16333
Annuals > 1 > income Statement > eps
-0.004405394470667566
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
3707500
Annuals > 1 > income Statement > income Tax Expense
0
Annuals > 1 > income Statement > EBITDA
-11077
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-5256
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
1255
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
1255
Annuals > 1 > balance Sheet > property Plant Equipment
-
Annuals > 1 > balance Sheet > total Assets
1255
Annuals > 1 > balance Sheet > payables
3300
Annuals > 1 > balance Sheet > short Term Debt
184966
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
216483
Annuals > 1 > balance Sheet > equity
-215228
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-16333
Annuals > 1 > cash Flow > depreciation
-
Annuals > 1 > cash Flow > change In Working Capital
-6257
Annuals > 1 > cash Flow > cash From Operations
-22590
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
21500
Annuals > 1 > cash Flow > net Change In Cash
-1089
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-0.004405394470667566
Annuals > 1 > ratios > PB
-0.0017225918560782054
Annuals > 1 > ratios > ROE
7.5886966379839045
Annuals > 1 > ratios > ROA
-1301.434262948207
Annuals > 1 > ratios > FCF
-22590
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
21
Annuals > 2 > quarter
2012-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
0
Annuals > 2 > income Statement > gross Profit
0
Annuals > 2 > income Statement > operating Expenses
7869
Annuals > 2 > income Statement > operating Income
-7869
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
-12787
Annuals > 2 > income Statement > net Income
-12787
Annuals > 2 > income Statement > eps
-0.0034489548213081592
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
3707500
Annuals > 2 > income Statement > income Tax Expense
0
Annuals > 2 > income Statement > EBITDA
-7869
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-4918
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
2344
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
2344
Annuals > 2 > balance Sheet > property Plant Equipment
-
Annuals > 2 > balance Sheet > total Assets
2344
Annuals > 2 > balance Sheet > payables
14813
Annuals > 2 > balance Sheet > short Term Debt
163466
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
201240
Annuals > 2 > balance Sheet > equity
-198896
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-12787
Annuals > 2 > cash Flow > depreciation
-
Annuals > 2 > cash Flow > change In Working Capital
7980
Annuals > 2 > cash Flow > cash From Operations
-4807
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
21500
Annuals > 2 > cash Flow > net Change In Cash
-4807
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.0034489548213081592
Annuals > 2 > ratios > PB
-0.0018640394980291208
Annuals > 2 > ratios > ROE
6.428988013836377
Annuals > 2 > ratios > ROA
-545.5204778156997
Annuals > 2 > ratios > FCF
-4807
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
20
Valuation > metrics > PE
-0.0003643964935940661
Valuation > metrics > PB
-0.0014683110165900333
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
0.5350473859509468
Profitability > metrics > ROA
-58.68809730668983
Profitability > final Score
16
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
0.1572052401746725
Risk > final Score
31
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.010651687056950897
Liquidity > metrics > Quick Ratio
0.010651687056950897
Liquidity > final Score
11
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
21
Prev Profitabilities > 1
19
Prev Profitabilities > 2
20
Prev Risks > 0
15
Prev Risks > 1
20
Prev Risks > 2
18
Prev Liquidities > 0
11
Prev Liquidities > 1
11
Prev Liquidities > 2
10
Updated At
2026-01-20T21:46:22.920Z
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport's syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease. The company also holds approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AJeld-Wen Shares Under Scrutiny Amid Leadership and Analyst Moves primaryignition.com
Read more →JELD-WEN Appoints Jeffrey Embt as Chief Accounting Officer The Globe and Mail
Read more →Showing 2 of 5
(Last Updated 2015-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of Ember Therapeutics Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2015-09-30)
(Last Updated 2015-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2015-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2015-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.